Related Experiment Video
Updated: Oct 20, 2025
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.4K
Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy
Chih-Hung Tsai1,2, Yuan-Ho Lin1,3, Yung-Sheng Li1,4
1Graduate Institute of Integrated Medicine, China Medical University, Taichung 40402, Taiwan.
International Journal of Molecular Sciences
|September 10, 2021
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a common cancer survivor side effect with limited treatments. Understanding CIPN pathogenesis is key to developing new therapeutic strategies and improving patient management.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Chemotherapy-induced peripheral neuropathy (CIPN) significantly impacts cancer survivor quality of life.
- Current prevention and treatment strategies for CIPN are insufficient.
- Elucidating CIPN pathogenesis is crucial for novel therapeutic development.
Purpose of the Study:
- To review the current understanding of CIPN pathogenesis.
- To summarize existing management recommendations and clinical trials for CIPN.
- To encourage translational research for improved CIPN strategies.
Main Methods:
- Comprehensive literature review of CIPN pathogenesis.
- Analysis of current clinical practice guidelines for CIPN.
- Survey of completed and ongoing clinical trials investigating CIPN treatments.
Main Results:
- The review consolidates current knowledge on CIPN mechanisms.
- It highlights the limitations of existing therapeutic interventions.
- It identifies active research directions and clinical trial outcomes.
Conclusions:
- A deeper understanding of CIPN pathogenesis is essential for effective treatment development.
- Translational research is vital to bridge the gap between basic science and clinical application.
- Improved strategies are needed to manage CIPN in cancer survivors.
Keywords:
alternative and complimentary medicinescancer survivorschemotherapy-induced peripheral neuropathynew drug developmentMore Related Videos
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
302
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
302
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
550
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
550
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
419
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
419
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
391
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
391
02:50Combination Therapies and Personalized Medicine
5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
01:26Peripheral Artery Disease IV: Nursing Management
96
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
96